Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing)- Global Forecast to 2031

The cardiac biomarkers market was valued at $5.15 billion in 2023. This market is expected to reach $10.08 billion by 2031 from an estimated $5.57 billion in 2024, at a CAGR of 8.8% during the forecast period of 2024-2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the cardiac biomarkers market is driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in cardiac biomarkers, increasing healthcare expenditure, and increasing cardiovascular disease awareness programs. However, limited specificity and sensitivity of biomarkers and high cost of biomarker testing restrain the growth of this market.

Furthermore, the introduction of novel biomarkers tests and integration of biomarkers in point-of-care testing are expected to generate market growth opportunities. However, the availability of alternative diagnostic technologies are major challenges in the global cardiac biomarkers market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over years (2021–2024). The key players operating in the cardiac biomarkers market are Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), BioMérieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc. (U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.).

Among all the type studied in this report, the troponin segment accounted for the largest share during the forecast period. The segment’s larger share can be attributed to its high specificity and sensitivity in diagnosing cardiovascular diseases, increasing burden of cardiovascular diseases and advancements in diagnostic technologies drives the market. growing number of product approvals and availability of troponin testing. For instance, in October 2024, Siemens Healthineers AG (Germany) received FDA approval of a new progressive claim for Atellica IM high-sensitivity troponin I (TnIH) test for predicting Heart Attack.

Among all the applications studied in this report, in 2024, myocardial infarction segment accounted for the largest share during the forecast period. The segment’s larger share can be attributed to the growing burden of diseases rapidly and mortality rate, increasing awareness about early diagnosis, advancements in point-of-care testing and rapidly growing geriatric population with high risk of myocardial infarction that demands for cardiac biomarkers.

Among all the end user studied in this report, in 2024, laboratory testing segment accounted for the largest share during the forecast period. The segment’s larger share can be attributed to the rising number of diagnostics laboratories, increasing awareness about early disease diagnosis, availability of skilled professionals, and increasing investments in developing healthcare infrastructure. laboratory testing can provide high throughput screening capacity for the samples which makes them more efficient for diagnosis procedure.

An in-depth analysis of the geographical scenario of the global cardiac biomarkers market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia Pacific is projected to register the highest CAGR during the forecast period. The fastest growth of the market is due to the rising number of cardiovascular diseases, robust healthcare infrastructure, widespread adoption of cardiac biomarkers as a diagnostic and prognostic tool for diseases are further expected to drive the cardiac biomarkers market in the region.

Scope of the Report:

Cardiac biomarkers Market Assessment—by Type

Troponin
Creatine kinase MB (CK-MB)
Myoglobin
B-Type Natriuretic Peptide (BNP)
N-terminal pro B-type natriuretic peptide (NT-proBNP)
Other Types ()

(Note: other types include Galectin, Homocysteine, C-Reactive Protein, and D-dimer)

Cardiac biomarkers Market Assessment—by Application

Myocardial Infarction
Congestive heart failure
Acute Coronary Syndrome
Other Applications
(Note: Other applications include Atherosclerosis, Pulmonary Embolism, and Atrial Fibrillation)

Cardiac biomarkers Market Assessment—by End User

Laboratory Testing
Point-of-care Testing

Cardiac biomarkers Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Switzerland
Netherlands
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
South Korea
Australia
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATAM)
Middle East & Africa